MarketCapExport financials
Ekso Bionics Holdings (EKSO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Ekso Bionics Holdings Cash Flow 2026-2011 | EKSO
Brief overview of Ekso Bionics Holdings's cash movements
The review uses the five latest available annual reports between 2021 and 2025.
The latest year produced an operating outflow of -$11.8 million. A return to positive cash generation is important.
Positive operating cash flow appeared only 0 times out of five; a stable cash profile has not formed.
Operating cash flow margin rose from -99.2% to -92.2%. The business generated more cash per unit of revenue.
Working capital needs increased $6.9 million, or 53.9% of sales. This may restrain cash conversion.
Cash flow takeaway
Ekso Bionics Holdings's cash flows remain vulnerable. Negative or unstable generation materially reduces financial flexibility.
Annual Cash Flow Ekso Bionics Holdings
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
39.1 M | -7.22 M | -9.85 M | -12.1 M | -14.7 M | -11.2 M | -8.76 M | -15.8 M | -22.2 M | -31.2 M | -25 M | -18.3 M | - | -12 K | - | - |
Depreciation & Amortization |
60.3 M | 80.7 M | 1.61 M | 1.7 M | 887 K | 1.02 M | 620 K | 690 K | 1.01 M | 1.2 M | 1.86 M | 933 K | 745 K | 469 K | 342 K | - |
Accounts Payables |
9.05 M | 3.96 M | 1.55 M | 1.85 M | 3.15 M | 3.11 M | 1.5 M | 1.9 M | 3.16 M | 2.42 M | 1.88 M | 2.69 M | 783 K | - | - | - |
Accounts Receivables |
12.5 M | 3.79 M | 7.24 M | 5.64 M | 4.62 M | 4.66 M | 3.39 M | 5.21 M | 3.66 M | 2.76 M | 1.78 M | 2.07 M | 1.55 M | - | - | - |
Total Inventories |
- | 4.82 M | 4.57 M | 5.05 M | 5.19 M | 2.24 M | 1.98 M | 2.49 M | 3.37 M | 3.02 M | 1.56 M | 1.06 M | 622 K | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Ekso Bionics Holdings
| 2026-Q4 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | -2.12 M | - | - | - | -1.96 M | - | - | - | -3.47 M | - | - | - | -4.21 M | - | -11 M | - | -4.21 M | - | -8.08 M | - | -2 M | - | -7.02 M | -5.74 M | -1.72 M | - | -14.3 M | -9.71 M | -5.18 M | - | -17 M | -12.8 M | -6.74 M | - | -25.6 M | -16.9 M | -7.25 M | - | -20.6 M | - | - | - | - | - | - | - | - | - | - | - | - | -27.2 K | - | - | -11.7 K | -9.9 K | -157 | - | - | - | - |
Depreciation & Amortization |
- | 454 K | - | - | - | 378 K | - | - | - | 406 K | - | - | - | 414 K | - | 632 K | - | 231 K | - | 782 K | - | 1 K | - | 465 K | 23 K | 13 K | - | 56 K | 55 K | 29 K | - | 119 K | 84 K | 43 K | - | 1.31 M | 866 K | 445 K | - | 1.38 M | 908 K | 440 K | - | 653 K | 419 K | 200 K | - | 535 K | 333 K | 157 K | - | 342 K | 227 K | 112 K | - | - | - | - | - | - | - | - |
Accounts Payables |
3.96 M | 2.11 M | 1.43 M | 1.55 M | 1.45 M | 2 M | 1.55 M | 1.81 M | 2.12 M | 1.88 M | 1.85 M | 2.5 M | 3.16 M | 3.04 M | 3.15 M | 2.39 M | - | 2.94 M | 3.11 M | 1.31 M | 1.43 M | 1.65 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 3.16 M | 3.16 M | 3.16 M | 3.16 M | 2.42 M | 2.42 M | 2.42 M | 2.42 M | 2.37 M | 1.88 M | 1.88 M | 1.88 M | 2.69 M | 2.69 M | 2.69 M | 2.69 M | 783 K | 783 K | 783 K | 783 K | 1.5 M | 1.5 M | 1.5 M | 1.5 M | - | - | - | - | - | - | - | - |
Accounts Receivables |
3.79 M | 4.54 M | 7.31 M | 5.64 M | 4.53 M | 6.46 M | 7.24 M | 6.96 M | 6.52 M | 7.24 M | 5.64 M | 5.87 M | 5.05 M | 4.83 M | 4.62 M | 3.4 M | - | 3.35 M | 4.66 M | 3.12 M | 2.76 M | 2.28 M | 3.22 M | 3.22 M | 3.22 M | 3.22 M | 5.21 M | 5.21 M | 5.21 M | 5.21 M | 3.66 M | 3.66 M | 3.66 M | 3.66 M | 2.76 M | 2.76 M | 2.76 M | 2.76 M | 1.78 M | 1.78 M | 1.78 M | 1.78 M | 2.07 M | 2.07 M | 2.07 M | 2.07 M | 1.55 M | 1.55 M | 1.55 M | 1.55 M | 549 K | 549 K | 549 K | 549 K | - | - | - | - | - | - | - | - |
Total Inventories |
- | 4.65 M | 4.82 M | 4.57 M | 5.44 M | 4.96 M | 4.57 M | 5.03 M | 4.97 M | 5.11 M | 5.05 M | 5.49 M | 5.6 M | 5.66 M | 5.19 M | 3.51 M | - | 2.77 M | 2.24 M | 1.75 M | 1.95 M | 2.15 M | 1.98 M | 1.98 M | 1.98 M | 1.98 M | 2.49 M | 2.49 M | 2.49 M | 2.49 M | 3.37 M | 3.37 M | 3.37 M | 3.37 M | 3.02 M | 3.02 M | 3.02 M | 3.02 M | 1.56 M | 1.56 M | 1.56 M | 1.56 M | 1.06 M | 1.06 M | 1.06 M | 1.06 M | 622 K | 622 K | 622 K | 622 K | 725 K | 725 K | 725 K | 725 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Ekso Bionics Holdings, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical instruments sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
electroCore
ECOR
|
$ 11.42 | 2.46 % | $ 96.9 K | USA |
 |
Alcon
ALC
|
$ 65.39 | 0.02 % | $ 32.3 B |  Schweiz |
 |
Glaukos Corporation
GKOS
|
$ 153.49 | 0.19 % | $ 8.78 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 106.82 | 0.01 % | $ 5.04 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 8.05 | 1.64 % | $ 357 M | USA |
 |
InfuSystem Holdings
INFU
|
$ 12.7 | 2.26 % | $ 262 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 111.75 | 1.1 % | $ 3.58 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 398.3 | 0.06 % | $ 142 B | USA |
 |
AngioDynamics
ANGO
|
$ 15.51 | 0.26 % | $ 644 M | USA |
 |
Repro Med Systems
KRMD
|
$ 3.27 | 2.42 % | $ 151 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 80.58 | 0.12 % | $ 1.82 B | USA |
 |
Microbot Medical
MBOT
|
$ 1.31 | 0.36 % | $ 60 M |  Israel |
 |
Merit Medical Systems
MMSI
|
$ 87.07 | 0.1 % | $ 5.15 B | USA |
 |
Nephros
NEPH
|
$ 4.29 | 2.88 % | $ 45.5 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 23.82 | 0.41 % | $ 4 B | USA |
 |
OraSure Technologies
OSUR
|
$ 3.99 | 8.13 % | $ 293 M | USA |
 |
Pro-Dex
PDEX
|
$ 71.94 | 0.12 % | $ 232 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 51.98 | 0.25 % | $ 3.5 B | USA |
 |
Repligen Corporation
RGEN
|
$ 184.53 | 0.81 % | $ 10.4 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.7 | 0.36 % | $ 21 M | USA |
 |
AtriCure
ATRC
|
$ 59.96 | 1.91 % | $ 2.86 B | USA |
 |
STAAR Surgical Company
STAA
|
$ 19.8 | 1.62 % | $ 981 M | USA |
 |
STERIS plc
STE
|
$ 209.98 | 0.61 % | $ 20.6 B | USA |
 |
Stereotaxis
STXS
|
$ 1.32 | 2.94 % | $ 120 M | USA |
 |
BioLife Solutions
BLFS
|
$ 37.74 | 0.37 % | $ 1.8 B | USA |
 |
Baxter International
BAX
|
$ 23.49 | 0.17 % | $ 12.1 B | USA |
 |
Utah Medical Products
UTMD
|
$ 75.01 | 2.93 % | $ 243 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 375.87 | 1.29 % | $ 27.2 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 182.52 | 0.01 % | $ 52.5 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 9.78 | 0.05 % | $ 1.95 B | USA |
 |
The Cooper Companies
COO
|
$ 56.07 | 1.41 % | $ 11.2 B | USA |
 |
ICU Medical
ICUI
|
$ 163.32 | 1.45 % | $ 4.02 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.42 | 4.73 % | $ 34.5 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 121.75 | 0.08 % | $ 5.43 B | USA |
 |
ResMed
RMD
|
$ 222.3 | 0.15 % | $ 32.3 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |